Skip to content

Measles-mumps-rubella vaccine (MMR) at 6 months of age: Long-term follow-up

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2026-526160-21-00
Enrollment
1000
Registered
2026-06-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

and rubella by vaccination, mumps, Prevention of measles

Brief summary

To measure the level of specific immunity, measured as level of measles neutralising antibodies by plaque-reduction neutralisation test 1-3 years after routine MMR vaccination at 4 years of age

Detailed description

• Level of specific immunity, measured as level of measles neutralising antibodies by plaque-reduction neutralisation test at least 1 year after MMR2. Level of specific immunity, measured as level of IgG against measles, mumps, and rubella at least 1 year after MMR2.

Interventions

Sponsors

Rigshospitalet
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
To measure the level of specific immunity, measured as level of measles neutralising antibodies by plaque-reduction neutralisation test 1-3 years after routine MMR vaccination at 4 years of age

Secondary

MeasureTime frame
• Level of specific immunity, measured as level of measles neutralising antibodies by plaque-reduction neutralisation test at least 1 year after MMR2. Level of specific immunity, measured as level of IgG against measles, mumps, and rubella at least 1 year after MMR2.

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 9, 2026